Preclinical relaxin therapy to reverse cardiac fibrosis and gain functional benefits

临床前松弛素疗法可逆转心脏纤维化并获得功能益处

• 批准号: nhmrc : 1081710
• 负责人: A/Pr Xiao-Jun Du
• 金额: $ 48.33万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-relaxin-therapy-functional-benefits/518821
• 关键词: Preclinical; relaxin; therapy; reverse; cardiac

Cardiac fibrosis is a key factor promoting heart disease and onset of complications including arrhythmias and heart failure. There is urgent and unmet need of drugs that can reverse fibrosis. By documenting anti-fibrotic action of a peptide hormone relaxin, CIA and his team will test therapeutic effect of relaxin in heart disease models focusing on fibrosis-reversal and functional gain, particularly arrhythmias. This work would promote development of relaxin as a new cardiovascular drug.

心脏纤维化是促进心脏病和并发症（包括心律失常和心力衰竭）发生的关键因素。对可以逆转纤维化的药物存在迫切且未满足的需求。通过记录肽激素松弛素的抗纤维化作用，CIA和他的团队将测试松弛素在心脏病模型中的治疗效果，重点是纤维化逆转和功能获得，特别是心律失常。这一工作将促进松弛素作为一种新型心血管药物的开发。